Sell

India’s markets regulator issued a statement urging investors to stay calm and exercise caution in response to reports from US-based shortseller Hindenburg Research. The report in question alleged that the head of Securities and Exchange Board of India (SEBI), Madhabi Puri Buch, had previous investments in offshore funds also utilized by the Adani Group. Despite
0 Comments
The cryptocurrency market experienced significant volatility as Bitcoin dropped below $50,000 for the first time since February. This led to a ripple effect on bitcoin-related companies, with names like Robinhood, MicroStrategy, Coinbase, and Marathon Digital all facing losses. Robinhood plummeted more than 10%, while MicroStrategy plunged more than 8%. This highlights how closely tied these
0 Comments
The widening of U.S. junk bond spreads over yields on risk-free Treasuries on Monday indicated that financial markets were perceiving more risk. This came after the biggest daily point surge since March 2023, with stocks seeing a sharp decline as investors sought the safety of U.S. government debt. The ICE/BofA U.S. high yield index option
0 Comments
In the last quarter, Berkshire Hathaway’s cash pile swelled to a record $276.9 billion, marking a significant increase from the previous record of $189 billion set in the first quarter of 2024. This surge came as Warren Buffett, the Oracle of Omaha, sold off large portions of stock holdings, including a significant portion of his
0 Comments
Chevron experienced a disappointing midday trading session, with stock slipping more than 3% due to second-quarter earnings missing Wall Street estimates. This news caused concern among investors, as adjusted earnings per share were reported at $2.55, lower than the $2.93 per share that analysts had expected. Additionally, revenue came in slightly higher than expected at
0 Comments
Moderna, a prominent biotech company, recently reported second-quarter revenue that exceeded expectations. However, the company decided to reduce its full-year sales guidance due to various factors such as lower expected sales in Europe, a competitive environment for respiratory vaccines in the U.S., and the potential for deferred international revenue into 2025. The company now anticipates
0 Comments